Journey Medical (DERM)
(Delayed Data from NSDQ)
$6.99 USD
-0.36 (-4.90%)
Updated Aug 1, 2025 03:59 PM ET
After-Market: $6.99 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth F Momentum C VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
DERM 6.99 -0.36(-4.90%)
Will DERM be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for DERM based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for DERM
Journey Medical Corporation (DERM) Reports Q1 Loss, Tops Revenue Estimates
Aurinia Pharmaceuticals (AUPH) Surpasses Q1 Earnings and Revenue Estimates
DERM: What are Zacks experts saying now?
Zacks Private Portfolio Services
The Joint Corp. (JYNT) Reports Q1 Loss, Tops Revenue Estimates
Lyra Therapeutics, Inc. (LYRA) Reports Q1 Loss, Lags Revenue Estimates
Strength Seen in Profound Medical (PROF): Can Its 8.3% Jump Turn into More Strength?
Other News for DERM
DERM: B. Riley Securities Raises Price Target for Journey Medical | DERM Stock News
New Price Target for Journey Medical (DERM)
Journey Medical price target raised by $3 at B. Riley, here's why
DERM Expands Coverage for Rosacea Treatment Emrosi | DERM Stock News